News

TyraTech Receives Head Lice Product Registration in UK
11 December 2012

TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has received notification from the U.K. regulatory body, the Medicines and Healthcare products Regulatory Agency ('MHRA'), that the Company's head lice product VaMOUSSE!™ has been registered with the MHRA as a Class I medical device. As a Class I medical device, VaMOUSSE!™ will be subject to the lowest level of regulatory oversight.

David Paton, TyraTech's Head of European Operations, said, "We are excited to have received our first product registration in the UK. VaMOUSSE!™ is the first in a range of products we envision for the removal, treatment and prevention of head lice infestations. We are actively seeking retail partners to distribute our product under their own store brands or through other channels under our brand VaMOUSSE!™. We expect the product to be launched in the first half of 2013."

For further information please contact:

TyraTech Inc.
Alan Reade, Executive Chairman
Tel: +1 919 415 4310

Peter Jerome, Chief Financial Officer
Tel: +1 919 415 4280

N+1 Singer, Nominated Adviser and Joint Broker
Aubrey Powell / Alex Wright
Tel: +44 20 3205 7500

First Columbus LLP, Joint Broker
Chris Crawford
Tel: +44 20 3002 2070

 

<< Back to News releases

Disclaimer for U.S. Site Visitors

This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.